|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gustavsson B, Carlsson G, Machover D,
Petrelli N, Roth A, Schmoll HJ, Tveit KM and Gibson F: A review of
the evolution of systemic chemotherapy in the management of
colorectal cancer. Clin Colorectal Cancer. 14:1–10. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lage H: An overview of cancer multidrug
resistance: A still unsolved problem. Cell Mol Life Sci.
65:3145–3167. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kathawala RJ, Gupta P, Ashby CR Jr and
Chen ZS: The modulation of ABC transporter-mediated multidrug
resistance in cancer: A review of the past decade. Drug Resist
Updat. 18:1–17. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Binkhathlan Z and Lavasanifar A:
P-glycoprotein inhibition as a therapeutic approach for overcoming
multidrug resistance in cancer: Current status and future
perspectives. Curr Cancer Drug Targets. 13:326–346. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Callaghan R: Providing a molecular
mechanism for P-glycoprotein; why would I bother? Biochem Soc
Trans. 43:995–1002. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Breier A, Gibalova L, Seres M, Barancik M
and Sulova Z: New insight into P-glycoprotein as a drug target.
Anticancer Agents Med Chem. 3:159–170. 2013. View Article : Google Scholar
|
|
8
|
Yang K, Wu J and Li X: Recent advances in
the research of P-glycoprotein inhibitors. Biosci Trends.
2:137–146. 2008.PubMed/NCBI
|
|
9
|
Liu J, Wang S, Zhang Y, Fan HT and Lin HS:
Traditional Chinese medicine and cancer: History, present
situation, and development. Thorac Cancer. 6:561–569. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nie J, Zhao C, Deng LI, Chen J, Yu B, Wu
X, Pang P and Chen X: Efficacy of traditional Chinese medicine in
treating cancer. Biomed Rep. 4:3–14. 2016.PubMed/NCBI
|
|
11
|
Li C, Hashimi SM, Cao S, Qi J, Good D,
Duan W and Wei MQ: Chansu inhibits the expression of cortactin in
colon cancer cell lines in vitro and in vivo. BMC Complement Altern
Med. 15:2072015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Qi F, Li A, Inagaki Y, Kokudo N, Tamura S,
Nakata M and Tang W: Antitumor activity of extracts and compounds
from the skin of the toad Bufo bufo gargarizans Cantor. Int
Immunopharmacol. 11:342–349. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yu CH, Kan SF, Pu HF, Jea Chien E and Wang
PS: Apoptotic signaling in bufalin- and cinobufagin-treated
androgen-dependent and -independent human prostate cancer cells.
Cancer Sci. 99:2467–2476. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Qi F, Inagaki Y, Gao B, Cui X, Xu H,
Kokudo N, Li A and Tang W: Bufalin and cinobufagin induce apoptosis
of human hepatocellular carcinoma cells via Fas- and
mitochondria-mediated pathways. Cancer Sci. 102:951–958. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Baek SH, Kim C, Lee JH, Nam D, Lee J, Lee
SG, Chung WS, Jang HJ, Kim SH and Ahn KS: Cinobufagin exerts
anti-proliferative and pro-apoptotic effects through the modulation
ROS-mediated MAPKs signaling pathway. Immunopharmacol
Immunotoxicol. 37:265–273. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang G, Wang C, Sun M, Li J, Wang B, Jin
C, Hua P, Song G, Zhang Y, Nguyen LL, et al: Cinobufagin inhibits
tumor growth by inducing intrinsic apoptosis through AKT signaling
pathway in human nonsmall cell lung cancer cells. Oncotarget.
7:28935–28946. 2016.PubMed/NCBI
|
|
17
|
Hu Q, Liang B, Sun Y, Guo XL, Bao YJ, Xie
DH, Zhou M, Duan YR, Yin PH and Peng ZH: Preparation of
bufalin-loaded pluronic polyetherimide nanoparticles, cellular
uptake, distribution, and effect on colorectal cancer. Int J
Nanomedicine. 9:4035–4041. 2014.PubMed/NCBI
|
|
18
|
Yin P, Wang Y, Qiu Y, Hou L, Liu X, Qin J,
Duan Y, Liu P, Qiu M and Li Q: Bufalin-loaded mPEG-PLGA-PLL-cRGD
nanoparticles: Preparation, cellular uptake, tissue distribution,
and anticancer activity. Int J Nanomedicine. 7:3961–3969.
2012.PubMed/NCBI
|
|
19
|
Qiu YY, Hu Q, Tang QF, Feng W, Hu SJ,
Liang B, Peng W and Yin PH: MicroRNA-497 and bufalin act
synergistically to inhibit colorectal cancer metastasis. Tumour
Biol. 35:2599–2606. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang Z, Zhang L, Ni Z, Sun J, Gao H, Cheng
Z, Xu J and Yin P: Resveratrol induces AMPK-dependent MDR1
inhibition in colorectal cancer HCT116/L-OHP cells by preventing
activation of NF-κB signaling and suppressing cAMP-responsive
element transcriptional activity. Tumour Biol. 36:9499–9510. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhou RP, Chen G, Shen ZL and Pan LQ:
Cinobufacin suppresses cell proliferation via miR-494 in BGC-823
gastric cancer cells. Asian Pac J Cancer Prev. 15:1241–1245. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fu L, Liang Y, Deng L, Ding Y, Chen L, Ye
Y, Yang X and Pan Q: Characterization of tetrandrine, a potent
inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer
Chemother Pharmacol. 53:349–356. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang L, Lin G, Kovács B, Jani M, Krajcsi
P and Zuo Z: Mechanistic study on the intestinal absorption and
disposition of baicalein. Eur J Pharm Sci. 31:221–231. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ambudkar SV: Drug-stimulatable ATPase
activity in crude membranes of human MDR1-transfected mammalian
cells. Methods Enzymol. 292:504–514. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kathawala RJ, Chen JJ, Zhang YK, Wang YJ,
Patel A, Wang DS, Talele TT, Ashby CR Jr and Chen ZS: Masitinib
antagonizes ATP-binding cassette subfamily G member 2-mediated
multidrug resistance. Int J Oncol. 44:1634–1642. 2014.PubMed/NCBI
|
|
26
|
Chen LM, Liang YJ, Ruan JW, Ding Y, Wang
XW, Shi Z, Gu LQ, Yang XP and Fu LW: Reversal of P-gp mediated
multidrug resistance in-vitro and in-vivo by FG020318. J Pharm
Pharmacol. 56:1061–1066. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim HJ, Lee KY, Kim YW, Choi YJ, Lee JE,
Choi CM, Baek IJ, Rho JK and Lee JC: P-glycoprotein confers
acquired resistance to 17-DMAG in lung cancers with an ALK
rearrangement. BMC Cancer. 15:5532015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu Q, Yang Z, Nie Y, Shi Y and Fan D:
Multi-drug resistance in cancer chemotherapeutics: Mechanisms and
lab approaches. Cancer Lett. 347:159–166. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Coley HM: Overcoming multidrug resistance
in cancer: Clinical studies of P-glycoprotein inhibitors. Methods
Mol Biol. 596:341–358. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chai S, To KK and Lin G: Circumvention of
multi-drug resistance of cancer cells by Chinese herbal medicines.
Chin Med. 5:262010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hu T, To KK, Wang L, Zhang L, Lu L, Shen
J, Chan RL, Li M, Yeung JH and Cho CH: Reversal of P-glycoprotein
(P-gp) mediated multidrug resistance in colon cancer cells by
cryptotanshinone and dihydrotanshinone of Salvia miltiorrhiza.
Phytomedicine. 21:1264–1272. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen G, Wang K, Yang BY, Tang B, Chen JX
and Hua ZC: Synergistic antitumor activity of oridonin and arsenic
trioxide on hepatocellular carcinoma cells. Int J Oncol.
40:139–147. 2012.PubMed/NCBI
|
|
33
|
Aspenström-Fagerlund B, Tallkvist J,
Ilbäck NG and Glynn AW: Oleic acid increases intestinal absorption
of the BCRP/ABCG2 substrate, mitoxantrone, in mice. Toxicol Lett.
237:133–139. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zamek-Gliszczynski MJ, Xiong H, Patel NJ,
Turncliff RZ, Pollack GM and Brouwer KL: Pharmacokinetics of 5 (and
6)-carboxy-2′,7′-dichlorofluorescein and its diacetate promoiety in
the liver. J Pharmacol Exp Ther. 304:801–809. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu KJ, He JH, Su XD, Sim HM, Xie JD, Chen
XG, Wang F, Liang YJ, Singh S, Sodani K, et al: Saracatinib
(AZD0530) is a potent modulator of ABCB1-mediated multidrug
resistance in vitro and in vivo. Int J Cancer. 132:224–235. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhao XQ, Xie JD, Chen XG, Sim HM, Zhang X,
Liang YJ, Singh S, Talele TT, Sun Y, Ambudkar SV, et al: Neratinib
reverses ATP-binding cassette B1-mediated chemotherapeutic drug
resistance in vitro, in vivo, and ex vivo. Mol Pharmacol. 82:47–58.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ma B, Chai S, Li N, To KK, Kan WL, Yang D
and Lin G: Reversal of P-glycoprotein-mediated multidrug resistance
by a synthetic α-aminoxy peptidomimetic. Int J Pharm. 424:33–39.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dwivedi GR, Tiwari N, Singh A, Kumar A,
Roy S, Negi AS, Pal A, Chanda D, Sharma A and Darokar MP: Gallic
acid-based indanone derivative interacts synergistically with
tetracycline by inhibiting efflux pump in multidrug resistant E.
coli. Appl Microbiol Biotechnol. 100:2311–2325. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mi Y and Lou L: ZD6474 reverses multidrug
resistance by directly inhibiting the function of P-glycoprotein.
Br J Cancer. 97:934–940. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mi YJ, Liang YJ, Huang HB, Zhao HY, Wu CP,
Wang F, Tao LY, Zhang CZ, Dai CL, Tiwari AK, et al: Apatinib
(YN968D1) reverses multidrug resistance by inhibiting the efflux
function of multiple ATP-binding cassette transporters. Cancer Res.
70:7981–7991. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR,
Liu DG, Ashby CR Jr, Huang Y, Robey RW, Liang YJ, et al: Lapatinib
(Tykerb, GW572016) reverses multidrug resistance in cancer cells by
inhibiting the activity of ATP-binding cassette subfamily B member
1 and G member 2. Cancer Res. 68:7905–7914. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shi Z, Peng XX, Kim IW, Shukla S, Si QS,
Robey RW, Bates SE, Shen T, Ashby CR Jr, Fu LW, et al: Erlotinib
(Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B
member 1 and ATP-binding cassette subfamily G member 2-mediated
drug resistance. Cancer Res. 67:11012–11020. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chufan EE, Sim HM and Ambudkar SV:
Molecular basis of the polyspecificity of P-glycoprotein (ABCB1):
Recent biochemical and structural studies. Adv Cancer Res.
125:71–96. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang T, Sun Y, Ma W, Yang Z, Yang J, Liu
J, Fan H, Yang Y, Gu J, Fawcett JP, et al: Trantinterol, a novel
β2-adrenoceptor agonist, noncompetitively inhibits P-glycoprotein
function in vitro and in vivo. Mol Pharm. 12:1–9. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
McCormick JW, Vogel PD and Wise JG:
Multiple drug transport pathways through human P-glycoprotein.
Biochemistry. 54:4374–4390. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Aller SG, Yu J, Ward A, Weng Y,
Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, Urbatsch IL,
et al: Structure of P-glycoprotein reveals a molecular basis for
poly-specific drug binding. Science. 323:1718–1722. 2009.
View Article : Google Scholar : PubMed/NCBI
|
